Medicus Pharma (NASDAQ:MDCX – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($11.64) EPS for the quarter, missing analysts’ consensus estimates of ($6.68) by ($4.96), FiscalAI reports.
Medicus Pharma Price Performance
NASDAQ:MDCX traded up $0.04 during mid-day trading on Friday, reaching $1.87. The stock had a trading volume of 29,253 shares, compared to its average volume of 97,217. The company has a market capitalization of $2.36 million, a price-to-earnings ratio of -0.02 and a beta of 0.80. Medicus Pharma has a 1-year low of $1.70 and a 1-year high of $127.50. The stock’s 50 day simple moving average is $6.14 and its two-hundred day simple moving average is $21.72.
Analyst Ratings Changes
MDCX has been the subject of several research analyst reports. Wall Street Zen upgraded Medicus Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 31st. Weiss Ratings raised shares of Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. Finally, Alliance Global Partners restated a “buy” rating on shares of Medicus Pharma in a research note on Monday, September 14th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Medicus Pharma has a consensus rating of “Moderate Buy” and an average price target of $450.00.
Check Out Our Latest Analysis on MDCX
About Medicus Pharma
Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes.
Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.
Read More
- Five stocks we like better than Medicus Pharma
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
